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Generic equivalencyGlatiramer acetate (GA) has been available under the brand name Copaxone® for nearly two decades. Recently,
the US Food and Drug Administration (FDA) approved the ﬁrst generic GA, Glatopa™, as fully substitutable for all
indications for which Copaxone 20 mg is approved; Glatopa also represents the ﬁrst FDA-approved “AP-rated,”
substitutable generic for treating patients with MS. Glatiramer acetate is a complex mixture of polypeptides
and, consequently, its characterization presented challenges not generally encountered in drug development.
Despite its complexity, and without requiring any clinical data, approval was accomplished through an
Abbreviated New Drug Application in which equivalence to Copaxone was evaluated across four criteria:
starting materials and basic chemistry; structural signatures for polymerization, depolymerization, and
puriﬁcation; physicochemical properties; and biological and immunological properties. This article
describes the rigorous overall scientiﬁc approach used to successfully establish equivalence between
Glatopa and Copaxone, and presents key representative data from several of the comprehensive sets of
physicochemical (structural) and biological (functional) assays that were conducted.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Glatiramer acetate (GA; Copaxone®, Teva Pharmaceuticals USA Inc.,
North Wales, PA, USA) is approved for the treatment of relapsing forms
of multiple sclerosis (MS) [1]. Its mechanism of action is complex and
involves immunomodulation of both the innate and adaptive immune
systems [2]. Known mechanisms include alteration of regulatory T-cell
function [3–5], with induction of a T-helper 1 (Th1) to Th2 cell shift
resulting in amore anti-inﬂammatory cytokineproﬁle [6–10], alteration
of antigen-presenting cell (APC) function [3], and modulation of B-cellation; APC, antigen-presenting
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. This is an open access article underfunction [2]. The possible neuroprotective effects of GA, which aremedi-
ated by neurotrophic factors, include the ability to reduce demyelination
and promote remyelination [2]. Glatiramer acetate is considered a
disease-modifying therapy that is dosed as a baseline immunomodula-
tory agent administered for extended periods of time [11,12]. Glatiramer
acetate and similar therapies are indicated to reduce the frequency
of exacerbations in patients with relapsing MS [1,12–16], and are
commonly initiated when patients show signs of relapsing MS [12].
Due to the widespread use and relatively high cost of Copaxone,
there is increasing interest in the development of generic versions of
GA to reduce costs and increase access to this medication for patients
with MS. Recently, the US Food and Drug Administration (FDA)
approved the ﬁrst generic GA, Glatopa™, which has been approved as
a fully substitutable generic for all indications for which Copaxone
20 mg is approved [17].
In the United States, a generic drug is approved under anAbbreviated
New Drug Application (ANDA). Using this process, preclinical or clinical
data are generally not required to establish safety and effectiveness of
the generic drug [18]. Instead, generics must demonstrate therapeutic
equivalence (i.e., pharmaceutical equivalence and bioequivalence) to
the innovator drug product [19]. Bioequivalence is deﬁned by the Code
of Federal Regulations, 21CFR320.1, as the “absence of a signiﬁcant dif-
ference in the rate and extent to which the active ingredient or active
moiety in pharmaceutical equivalents or pharmaceutical alternativesthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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same molar dose under similar conditions in an appropriately designed
study [19].” Per Code of Federal Regulations 21CFR320.22 [20], and as
is routinely determined for injectable products, the bioequivalence
of Glatopa has been deemed self-evident based on the fact that it is a par-
enteral solution intended solely for administration by injection and that
it contains the same active and inactive ingredients in the same concen-
trations as the approved drug product, Copaxone. Although GA is a mix-
ture of polypeptides, it is produced by a completely chemical synthesis
and is not a biologic; therefore, the ANDA process was the appropriate
regulatory pathway.
Establishing pharmaceutical equivalence involves demonstrating
“sameness” of the active ingredient, as well as other product character-
istics, such as dosage form and concentration. While the latter qualities
are easily veriﬁed, demonstrating “sameness” of the active ingredient
requires both detailed characterization of the active ingredient and de-
velopment of a process that reproducibly yields an equivalent material.
Most generic medicines approved to date consist of small-molecule,
one-component active ingredients, where the demonstration of same-
ness can be achieved through ﬁrst-principle chemical analysis and the
chemical connections can be fully ascribed. The development of the pro-
cess to produce a generic is typically designed to make the correct end
product, while minimizing the levels of side-products and impurities.
These processes need not be similar to the brand process, and the char-
acterization of the process is not a critical component of the demonstra-
tion of sameness of the active ingredient.While the size and complexity
of the generics approved in recent years has increased, most generics
still follow this simple model of proof of structure and quality via direct
chemical analysis.
Glatiramer acetate, however, is a complex mixture of synthetic poly-
peptideswith a range ofmolecularweights and sequences,manufactured
from the copolymerization of the amino acids L-alanine, L-glutamic acid,
L-lysine, and L-tyrosine in a speciﬁc molar ratio [1,6,10]. Therefore, due
to the large number of possible components, structural elucidation by
complete component analysis is not possible. However, the exact analysis
of each component is neither practical nor necessary, and the equivalence
of Glatopa to Copaxone was demonstrated by a comprehensive set of
physicochemical and biological characterization techniques, in combina-
tion with a thorough understanding of the process used to make GA.
The combination of thorough product characterization and process
understanding was utilized to achieve and demonstrate equivalence of
the GA in Glatopa and Copaxone, the reference listed drug.
2. Materials and methods
A strategy was developed to establish equivalence based on an
understanding of the chemistry, manufacturing process, and biology of
GA. The following four-point criteria were employed for evaluating
the equivalence of Glatopa to Copaxone.
• Equivalence of starting materials and basic chemistry
• Equivalence of structural signatures for polymerization, depolymeri-
zation, and puriﬁcation
• Equivalence of physicochemical properties
• Equivalence of biological and immunological properties
Using this framework, this article describes the process of establish-
ing sameness and presents data demonstrating the equivalence of
Glatopa to Copaxone 20 mg.
3. Results and discussion
3.1. Characterization of the reference listed drug
To develop an equivalent product and process, a thorough under-
standing of the brand productwasﬁrst required. Thiswas accomplishedby a review of the available scientiﬁc, patent, and regulatory literature
on Copaxone and by extensive physicochemical, biological, and im-
munological characterization of Copaxone. These characterizations
involved the use of more than 60 methods, with up to 50 different
Copaxone lots being measured for some attributes. In addition to de-
scribing Copaxone, the use of multiple-lot testing served to measure
and express the diversity and range of the commercial lots of Copaxone
for certain quantitative attributes. The data from these analyses are pre-
sented as examples of the application of the four equivalence criteria,
which are discussed in the following sections.
3.2. Equivalence of starting materials and basic chemistry
The chemical process used to manufacture the drug substance
for Copaxone is relatively straightforward and well understood; the
basic framework (i.e., identity of reagents, solvents, ratios, and process-
ing steps) have been available in the public literature for many years
[21]. It consists of three basic chemical steps, followed by a ﬁnal puriﬁca-
tion step (Fig. 1): 1) polymerization of four amino acid N-
carboxyanhydrides (NCAs) initiated by diethylamine; 2) depolymeriza-
tion and deprotection of the initially formed protected polypeptide mix-
ture; and 3) ﬁnal deprotection of the second intermediate polypeptide
mixture, followed by puriﬁcation and counter ion-exchange.
The same startingmaterials (NCAs)with the same protecting groups
are used for the manufacture of both Glatopa and Copaxone. Similarly,
the same solution-phase polymerization, HBr-based depolymerization,
and deprotection chemistry are applied in the synthesis of both Glatopa
and Copaxone. The identities of the startingmaterials, reagents, and sol-
vents have been previously described [1,22] and were conﬁrmed
through the detection of residual materials, such as protecting groups
in the brand product (i.e., Lys[TFA] and Glu[OBn]). The starting mate-
rials were extensively investigated with several conventional analytical
methods (i.e., spectroscopic, chromatographic, and chiral purity and im-
purity analysis), and the effects of the starting material quality were
assessed (e.g., the impact of NCA impurities on product attributes).
3.3. Equivalence of structural signatures for polymerization, depolymerization,
and puriﬁcation
As noted, GA is a complexmixture of polypeptides and its character-
ization presents challenges not generally encountered in generic drug
development. However, while GA is complex, it is not complicated
and is produced by a process that is well documented, well understood,
and decipherable. Consequently, the impact of process conditions on
speciﬁc product attributes can be elucidated experimentally. The prod-
uct attributes that are directly attributable and sensitive to the processes
of polymerization, depolymerization, and puriﬁcation are referred to as
process signatures. As part of the development of generic GA, a thorough
understanding of this processwas developed by coupling the analysis of
GA process signatures with process development. The demonstration of
the equivalence of process signatures for the three steps in both the
Glatopa and Copaxone processes ensures that the processes used to
manufacture the two materials are equivalent.
It should be noted that process conditions need not be identical to
produce equivalent material. In fact, extensive process characterization
studies were performed to not only discover the process signatures but
to also deﬁne the acceptable ranges for all critical process conditions
(e.g., reaction temperatures, concentration of reactants) that inﬂuenced
the corresponding process signatures. The total evaluation comprised
developing the analytical methods appropriate for measuring process
signatures speciﬁc to each of the chemical steps used to produce GA,
and deﬁning the range of process conditions that produce equivalent
and nonequivalent process signatures. Therefore, comparing different
lots of GA on the basis of process signatures can demonstrate whether
or not equivalent processes were used to produce the materials. GA
Fig. 1. Synthetic scheme for glatiramer acetate.
Table 1
Selected process signatures for each step in the glatiramer acetate process.
Process step Chemistry Glatiramer acetate
structural signature
1. Polymerization Reagents/charge • Amino acid proportions
• Total diethylamide content
Initiation • Amino acid diethylamide
proportions
Propagation • N-terminal amino acid
sequence
2. Depolymerization/
deprotection
Cleavage
preferences
• C-terminal amino acid
proportions
• N-terminal amino acid
proportions
• Pyroglutamate content
• Molar mass distribution
3. Deprotection/
puriﬁcation
Removal of
small peptides
• Molar mass distribution
• Amino acid proﬁle across
molar mass distribution
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equivalent.
Structural signatures for each process step were developed through
understanding of the chemistry and extensive mathematical modeling
of differential reaction kinetics. Each process signaturewas demonstrat-
ed to havemeasurable and consistent effects on the ﬁnal product. Some
structural signatures selected as being representative of each step of the
manufacturing process are shown in Table 1.
One example of how process conditions create process signatures in
the ﬁnal product is the effect of composition drift, a concept that has
been described in polymer chemistry since 1930 [23]. Speciﬁcally,
because the monomers differ in reactivity, the initiation and polymeri-
zation reactions consume monomers nonuniformly, causing the reac-
tant proportions to change over the course of the reaction. Thus, the
polymer composition varies in a controlled and predictable manner as
the polymer chains grow. This composition drift deﬁnes the sequences
generated by the process.
The process signatures that are due to composition drift are used
to characterize the ﬁrst step of the process in the synthesis of GA.
Fig. 2 describes the polymerization reaction that occurs in step 1 of
the process. The polymerization is initiated by the reaction of one
NCA with diethylamine (DEA) and is propagated by reaction of the
N-terminus of that amino acidwith a subsequent amino acid. The abun-
dance of amino acids at the beginning of the chain (near the DEA) is
governed by the relative amount of each NCA present and the differen-
tial reaction kinetics between each NCA and the growing polymer,
with themost reactive amino acids dominating. As the chains propagateand NCAs are depleted, the ratio of amino acids available for reaction
changes so that the ends of the chains have proportionally more of the
less reactive amino acids. This is referred to as composition drift and
can be monitored by several process signatures.
For example, the proportion of each amino acid that is adjacent to
DEA in the ﬁnal GA (i.e., as an amino acid diethylamide) is different
from the bulk ratio of the amino acids in the product; subsequently,
the ratio of amino acid diethylamides can be monitored as a reﬂection
Fig. 2. Pictorial representation of the step 1 N-carboxyanhydride polymerization and step 2 depolymerization of Intermediate-1. The ﬁgure demonstrates the composition drift in the in-
termediate 1 polymer, which is controlled by reaction kinetics, aswell as the origin of the C- andN-termini created in step 2, which are controlled by cleavage preferences. These diagrams
are illustrative only and do not represent the actual distribution sequence generated in step 1.
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levels of each diethylamide in the ﬁnal GA for multiple lots of Glatopa
and Copaxone. The levels for several lots of Glatopa and Copaxone
overlap, demonstrating not only equivalence of the ﬁnal products but,
speciﬁcally, equivalence of the step 1 polymerization reaction.
To conﬁrm that the differential reaction kinetics for step 1 do cause a
composition drift in the ﬁnal product, the generation of material under
conditions with different kinetics was performed. In one example, the
step 1 reaction was performed with a different solvent while the
remaining steps were performed as normal. The resulting material
was designated as a negative control because it matched the Copaxone
label speciﬁcations for amino acid composition and peak molecular
weight, but was known to have been made with different sequence
preferences due to the deliberate change to reaction kinetics. Fig. 3
also includes the results of the analysis for diethylamide content ofFig. 3.Relative level of each amino acid adjacent to diethylamine inﬁnal glatiramer acetate
for several lots of Glatopa, Copaxone, and a step 1 negative control,where the reactionwas
run in a different solvent and resulted in different relative reaction kinetics. Ala, alanine;
DEA, diethylamine; Glu, glutamate; Lys, lysine; Tyr, tyrosine.the negative control. In this case different amino acid diethylamide pro-
portions are observed, directly due to the different reaction kinetics for
the polymer initiation step of the process. Additional negative controls
were designed and used to conﬁrm the process signatures described
in Table 1. The use of such negative controls proves the sensitivities of
the analytical methods employed and validates understanding and con-
trol of the process.
In step 2 of the process, the long-chain polypeptides created in step 1
are cleaved to create smaller peptides, and the benzyl protecting group
on glutamic acid is removed (Fig. 2). The extent and sites of the cleav-
ages are governed by reaction conditions, such as time and temperature,
and also by the cleavage preferences (i.e., kinetics) of individual bonds.
These cleavage preferences are reﬂected in the C- and N-termini ob-
served in the ﬁnal GA. Fig. 4 shows the relative amino acid levels at
the N-termini of GA for the ﬁrst ﬁve cycles of N-terminal analysis by
Edman degradation. The results for four representative Glatopa lots
were contained within the acceptance criteria based on the observed
range for multiple lots of Copaxone. Because the N-terminal character-
istics are a combination of the composition drift from step 1 and the
cleavage preferences in step 2, the equivalence of this attribute further
conﬁrms the equivalence of GA processes.
As with the previous process signature example, negative controls
were used to probe the sensitivity of the N-terminal process signature
to different reaction conditions. The negative control shown in Fig. 3,
which used step 1 conditions where different reaction kinetics were
present, was also run by N-terminal analysis and the results are
shown in Fig. 4. For this sample, several points are beyond the speciﬁca-
tion limits, demonstrating the sensitivity of this measure to the step 1
process conditions. Results for a step 2 negative control are also
included in Fig. 4. In this sample, the depolymerization conditions
were modiﬁed, leading to alteration of the cleavage preferences and
subsequent changes in the N-terminal proﬁles.
The amino acids present at the C-terminiwere similarly examined to
demonstrate the equivalence of the step 2 processes. Fig. 5 shows the
relative levels of each amino acid at the C-termini that terminate in a
carboxylic acid. These are indicative of C-termini that are generated
during the step 2 cleavage reaction, as opposed to the C-termini that
result from the original initiation reaction and that are present as
amino acid diethylamides (Fig. 3). As with the N-termini, the results
for four representative Glatopa lots were contained within the accep-
tance criteria based on the observed range formultiple lots of Copaxone.
The step 2 negative control using the alternate depolymerization
Fig. 4. Relative amino acid levels at the N-termini of glatiramer acetate for the ﬁrst 5 cycles of N-terminal analysis by Edman degradation. The red lines represent the Copaxone-based
speciﬁcations for each amino acid for each cycle. Within these lines are the results for 4 representative Glatopa lots (blue). Also shown are 2 negative controls: one is a step 1 reaction
negative control (orange) where the reaction was run with a different solvent; the other is a step 2 negative control (green), in which the depolymerization reaction was altered.
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side the acceptance ranges were observed for three of the four amino
acids, demonstrating the sensitivity of this measure to the process
conditions.
Step 3 of the process is a ﬁnal deprotection of the lysine amino acid
followed by puriﬁcation and ﬁnal acetate salt exchange. An example of
a process signature of this step is the ﬁnal molar mass distribution.
Although the molar mass is in part determined by the step 2 cleavage,Fig. 5. Relative amino acid levels at the C-termini of glatiramer acetate. The solid lines fo
Within these lines are the results for multiple Glatopa lots. Also shown is a step 2 negative contr
quantiﬁes the C-termini that end in COOH, and does not include the peptides that termina
RLD = reference listed drug.the ﬁnal distribution is governed by step 3, wherein removal of small
peptides is achieved via diaﬁltration. Fig. 6A shows the overlay of the
molarmass distribution for lots of Glatopa and Copaxone, demonstrating
the equivalence of this attribute in both materials. To demonstrate the
sensitivity of this measure to the process, Fig. 6B shows the molar mass
distribution for a lot of GA before and after the diaﬁltration step. The be-
fore sample functions as a negative control for this step and comparison
of these chromatograms shows that the ﬁltration operation reduces ther each amino acid represent the Copaxone-based speciﬁcations for that amino acid.
ol, in which the depolymerization reaction was altered (black squares). Note: thismethod
te in diethylamide (see Fig. 3). Ala, alanine; Glu, glutamate; Lys, lysine; Tyr, tyrosine;
Fig. 6.A) overlay of themolarmass distributions ofGlatopa and Copaxone, asmeasuredby
size exclusion chromatography. Peptides elute by size, with large peptides eluting ﬁrst.
B) overlay of the molar mass distributions of a lot of glatiramer acetate lot before
(the step 3 solution) and after (ﬁnal GA solution) the diaﬁltration step.
Fig. 7. Overlaid circular dichroism spectra of Glatopa and Copaxone.
Fig. 8.Amino acid compositions asmole fractions ofﬁnal glatiramer acetate for several lots
of Glatopa and Copaxone. Ala, alanine; Glu, glutamate; Lys, lysine; Tyr, tyrosine.
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distribution on the right-hand side between the Intermediate-3 solution
and the GA solution.While both of these solutionsmeet the speciﬁcation
for peak molar mass, only the ﬁnal GA sample gives a polydispersity
within the Copaxone-based speciﬁcation, demonstrating the importance
of this process signature to the control and understanding of the process.
A comprehensive suite of methods has been developed to measure
the full complement of process signatures, analogous to the examples
given herein for each process step. As described, these methods
were also performed on negative controls (nonequivalent glatiramoid
materials) to conﬁrm their sensitivities to process changes. The mea-
surement of the complete set of process signatures was combined
with process design space experiments to achieve a full understanding
of each process step and its effect on the ﬁnal product. This allowed
for the establishment of a process for Glatopa that is equivalent to that
used to manufacture Copaxone.
3.4. Equivalence of physicochemical properties
In addition to the extensive, innovative, and proprietary approach
used to demonstrate the equivalence of process signatures, themethods
deﬁned in Section 3.3 form a subset of all the techniques used to study
the physicochemical attributes of GA. Approximately 45 different
methods were employed to characterize the drug substance and drug
product and to ensure the quality of the product. These included
many methods that are orthogonal to the ones previously described,
but also those that probed additional physicochemical attributes
(e.g., higher-order structure, chirality), bulk composition properties(e.g., amino acid content, nuclear magnetic resonance and infrared
spectral properties), and many that deﬁne general quality attributes
(e.g., impurities, concentration, potency).
An example of an additional method is the measure of circular
dichroism as an indication of the extent of secondary structure of the
polypeptide chains. Fig. 7 shows the spectra of a Copaxone lot and a
Glatopa lot, which demonstrate equivalence of the two materials
for this attribute. In fact, the level of α-helical content calculated
from these spectra was shown to be numerically the same for the two
materials. In another example, the total amino acid compositions
of numerous lots of Glatopa and Copaxone were shown to be
equivalent (Fig. 8).
3.5. Equivalence of biological and immunological properties
Having achieved the physicochemical equivalence of Glatopa
to Copaxone by matching the starting materials, process signatures,
and physicochemical properties, the biological functions of GA were
examined to demonstrate the equivalence of Glatopa to Copaxone in
aggregate biological function and in the key aspects of its biology.
Fig. 9. The biological and immunological evaluation of Glatopa vs Copaxone. A) Cells related to the various mechanisms of action of glatiramer acetate (GA). B) Assays covering aggregate
biological function and key aspects of GA biology (e.g., T- and B-cell biology). Ab, antibody; EAE, experimental autoimmune encephalomyelitis; ELISA, enzyme-linked immunosorbent
assay; mAB, monoclonal antibody; MBP, myelin basic protein; MHC, major histocompatibility complex; TCR, T-cell receptor.
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and immunological assays, including major histocompatibility com-
plex (MHC) II class binding, APC function, T-cell proliferation, T-cell
polarization, B-cell biology, antibody response, immunorecognition,
genome-wide gene expression effects [24], anti-inﬂammatory
effects, and neuroprotection. Fig. 9 illustrates this comprehensive
and rigorous approach, and the following are some examples.
The ﬁrst assay was based on the ability of GA to modulate the
immune system. Following subcutaneous administration, GA was
processed by the professional APCs (dendritic cells) and peptide
fragments were presented in the context of MHC class II antigen to
stimulate T-cell activation. Naive T cells initially responded to GA
through polyclonal, antigen-speciﬁc proliferation and cytokine produc-
tion. With repeated exposure to GA, the T-cell response to GA was
modulated over time toward a tolerogenic Th2-like phenotype. These
GA-reactive Th2-like cells are thought to migrate from the periphery
to the central nervous system (CNS) and exert an anti-inﬂammatory
effect on the local pathogenic inﬂammatory response through thesecretion of anti-inﬂammatory cytokines [2]. The broad (antigen non-
speciﬁc) suppression of pathogenic cells by GA-speciﬁc T cells
has been termed bystander suppression [5,25]. Secretion of the soluble
Th2 cytokine interleukin-4 (IL-4) from murine GA-speciﬁc Th2
polarized cells is a measure of T-cell activation [6]. Two key cell
types are required for GA-induced IL-4 secretion: antigen-speciﬁc
cells (murine splenocytes depleted of T cells) and murine GA-
responsive, Th2-polarized T cells [25]. GA-induced IL-4 secretion was
quantiﬁed using an IL-4 enzyme-linked immunosorbent assay
(ELISA), and the relative potency of Glatopa and Copaxone served as
a speciﬁc measure of biological equivalence. The relative potencies
for multiple lots of Glatopa compared to a reference lot of Copaxone
(chosen for its potency at the median of a panel of 11 RLD lots) were
between 93% and 107%, demonstrating equivalence with respect to
this biological response.
Aggregate measures of the efﬁcacy of GA were measured by the use
of in vivo animal models. Experimental autoimmune encephalomyelitis
(EAE) is the most commonly used animal model to mimic multiple
Fig. 10. Glatopa and Copaxone similarly delayed the onset of symptoms compared with controls in experimental autoimmune encephalomyelitis models. (A) Clinical scores: active
induction with proteolipid peptide (PLP)139–151. (B) Clinical scores: active induction with myelin oligodendrocyte glycoprotein (MOG35−55). (C) Clinical scores: adoptive transfer from
PLP139–151. FTY720, ﬁngolimod (used as a positive control; inhibited disease when given daily at 3 mg/kg).
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[4]. EAE models of relapsing–remitting and chronic and progressive
forms of MS have been developed and are used to predict potential
clinical efﬁcacy of new therapies for MS [26]. In fact, the EAE model is
currently used as a release test to conﬁrm the biological activityof Copaxone. EAE was induced with various immunogenic myelin
neuroantigens, either directly by immunization with these antigens
(i.e., active induction) or passively following transfer of lymphocytes
speciﬁc to these neuroantigens. Three different mouse EAE models
were used to compare the efﬁcacy of Glatopa and Copaxone [27].
Fig. 11. Histological analysis of myelin oligodendrocyte glycoprotein (MOG)35–55
active induction experimental autoimmune encephalomyelitis model. A) The
extent of demyelination, B) apoptotic cell counts, and C) inﬂammatory foci. NS, not
signiﬁcant. ***P b 0.001 vs. controls. One-way ANOVA followed by Tukey's method for
multiple comparisons.
Fig. 12. Sandwich enzyme-linked immunosorbent assay. An immunorecognition assay
using a panel of GA-speciﬁc monoclonal antibodies to map epitopes showed that the
EC50 values of three lots each of Glatopa and Copaxone were not signiﬁcantly different
for the monoclonal antibody pair shown (P= not signiﬁcant). C, Copaxone; G, Glatopa.
Fig. 13. B-cell biology. No statistically signiﬁcant differences in the antibody titers obtained
in mice immunized with Copaxone or Glatopa independent of the capture antigen.
C, Copaxone; G, Glatopa; NS, not signiﬁcant.
32 J. Anderson et al. / Journal of the Neurological Sciences 359 (2015) 24–34All animal experimentswere approved and performed under the guide-
lines of the Institutional Animal Care and Use Committee of Momenta
Pharmaceuticals, Inc. (IACUC approval number 05-2011).In the ﬁrstmodel, EAE is induced in SJL/J mice by immunizationwith
proteolipid peptide (PLP139–151). The active-induction PLP139–151 model
was chosen because it is a well-established simulation of relapsing–
remitting MS (RRMS) [28,29]. It simulates the various steps of auto-
immune antigen recognition and presentation, T-cell activation and
polarization, trafﬁcking of autoreactive inﬂammatory cells, initiation
of inﬂammation in the CNS, and eventual resolution of disease.
In the secondmodel, active inductionwas initiated by immunization
of C57Bl/6 mice with the neuroantigen myelin oligodendrocyte
glycoprotein (MOG35–55) [30]. This active induction model is a well-
established simulation of primary progressive MS. Similar to the
PLP139–151 model, MOG35–55 induction mimics the various steps of
autoimmune response but exhibits more neurodegeneration [26].
It was, therefore, chosen as a conﬁrmatory model to compare the
neuroprotective effects of Glatopa and Copaxone.
Finally, in the adoptive transfer model of EAE, SJL/J donor mice
were immunized with PLP139–151, donor spleens were removed,
and splenocytes were isolated for culture in the presence of PLP139–151.
Cells were then given intravenously to naive recipient SJL/J mice [27].
Glatopa or Copaxone at 2 mg was given daily on days 0 through 9. The
adoptive transfer PLP139–151 model is another well-established simula-
tion of RRMS that bypasses the T-cell activation process and focuses on
more downstream aspects of the disease, such as lymphocyte trafﬁcking,
homing to the CNS, and resolution of inﬂammation. This model was
chosen to compare the effects of Glatopa and Copaxone on these aspects
of the autoimmune response, using a different, daily therapeutic dosing
regimen [29].
33J. Anderson et al. / Journal of the Neurological Sciences 359 (2015) 24–34All three EAE models (Fig. 10) demonstrated equivalent efﬁcacy
between Glatopa and Copaxone and statistically signiﬁcant delays in
disease onset. In addition, histological examination of the MOG35–55
study (Fig. 11) conﬁrmed a strong inhibition of inﬂammation,
as measured by reduced immune cell inﬁltration, and evidence of
neuroprotection, as measured by diminished damage to myelin
sheaths and decreases in apoptotic cell counts. Importantly, there
was no signiﬁcant difference between Glatopa and Copaxone in any
of the following measured disease parameters: incidence, intensity,
mean peak score, and mean day of onset.
To assess the immunogenic potential of GA, in vitro and in vivo as-
says were employed. Unlike protein therapeutics, GA has secondary
but no tertiary structure. Unlike biological therapeutics, GA is also not
susceptible to aggregation, which could uncover epitopes that are
recognized by the immune system and thereby lead to the formation
of antibodies. Nevertheless, GA is considered a therapeutic vaccine,
and as such, the activation of the humoral immune system with
the resulting development of antibodies to Copaxone following
repeated treatment is well known [13,31]. These antibodies are
non-neutralizing and do not negatively impact the safety and efﬁca-
cy of Copaxone; in fact, high titers of antibodies have been correlated
with improved clinical response [32]. Differences in immunogenicity
were not expected between Glatopa and Copaxone, which had al-
ready demonstrated structural equivalence, but two immunological
methods were used to speciﬁcally conﬁrm this.
The ﬁrst was an immunorecognition assay using a panel of GA-
speciﬁc monoclonal antibodies (mAbs) to map epitopes. Epitope-
recognition testing using sandwich ELISA with GA-speciﬁc mAbs
showed that the EC50 values of three lots of Glatopa and three lots
of Copaxone were not statistically signiﬁcantly different for the
mAb pair shown (Fig. 12). The epitopes recognized by the mAbs
were found in the same abundance in both Glatopa and Copaxone.
This showed evidence of a similar “immuno-ﬁngerprint” between
these two versions of GA, and demonstrated that the amino acid
composition and sequences of both drugs are equivalent.
The second test was a formal in vivo demonstration of comparable
immunogenic potential of the twoGAs andwas performedbymeasuring
the temporal readout of antibody response (titer and isotype) in mice
and the cross-reactivity of antibodies generated in individual mice. The
antibody titers of mice treated with Copaxone or Glatopa were assessed
in a crossover design (Fig. 13). Sera samples frommice immunized with
Copaxone or Glatopa generated robust antibody titers at day 28 that
cross-reacted equally (i.e., there were no statistically signiﬁcant differ-
ences, P b 0.05) with both antigens within each individual animal.
These studies comprehensively demonstrate that there is no higher
risk of immunogenicity with Glatopa than with Copaxone.
4. Conclusions
A rigorous scientiﬁc approach enabled determination of equivalence
of a generic GA, Glatopa, with the reference listed drug, Copaxone
20 mg. The most challenging aspect of this was the demonstration of
active ingredient sameness, which was achieved using a four-point
criteria framework. These criteria included the equivalence of starting
materials, process signatures, physicochemical properties, and biologi-
cal and immunological attributes. The selected methods and data
presented here represent a small portion of the comprehensive set of
physicochemical and biological assays that were conducted. No differ-
ences were observed in structure or function between Glatopa and
Copaxone, as measured using more than 45 physicochemical methods
and more than 15 biological and immunological assays. In addition to
these multiple analyses, as part of the approval process under the
ANDA pathway, independent testing by FDA laboratories conﬁrmed
the equivalence of Glatopa and Copaxone [33].
The approval of Glatopa by the FDA as fully substitutable for
Copaxone 20 mg demonstrates that by using advanced analytics pairedwith extensive process knowledge, equivalence to the brand product
for a complex mixture such as GA is achievable. Furthermore, while
GA is not a biologic, the strategies employed and lessons learned in its
development, much like those used in the development of the generic
complex mixture drug enoxaparin [34], have applications in the devel-
opment of biosimilars (i.e., generic versions of complex biologic drugs).
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